{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:32:03Z","timestamp":1792715523336,"version":"4.5.0"},"reference-count":215,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"3","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Commun"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1002\/cac2.12639","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T12:02:08Z","timestamp":1735646528000},"page":"332-379","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update"],"prefix":"10.34133","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7668-9674","authenticated-orcid":false,"given":"Feng","family":"Wang","sequence":"first","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gong","family":"Chen","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Fudan University Shanghai Cancer Center","place":["Shanghai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-9553","authenticated-orcid":false,"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital","place":["Hangzhou, P. R. China"]},{"name":"Zhejiang University School of Medicine","place":["Hangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan\u2010Hong","family":"Gao","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Centre, The State Key Laboratory of Oncology in South China","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqi","family":"Sheng","sequence":"additional","affiliation":[{"name":"Fudan University Shanghai Cancer Center","place":["Shanghai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7950-787X","authenticated-orcid":false,"given":"Zixian","family":"Wang","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxiang","family":"Li","sequence":"additional","affiliation":[{"name":"Fudan University Shanghai Cancer Center","place":["Shanghai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglin","family":"Yuan","sequence":"additional","affiliation":[{"name":"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjun","family":"Cai","sequence":"additional","affiliation":[{"name":"Fudan University Shanghai Cancer Center","place":["Shanghai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ren","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital","place":["Shanghai, P. R. China"]},{"name":"Fudan University","place":["Shanghai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Liu","sequence":"additional","affiliation":[{"name":"The First Hospital of China Medical University","place":["Shenyang, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5441-8240","authenticated-orcid":false,"given":"Jianmin","family":"Xu","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital","place":["Shanghai, P. R. China"]},{"name":"Fudan University","place":["Shanghai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Harbin Medical University Cancer Hospital","place":["Harbin, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5924-7783","authenticated-orcid":false,"given":"Houjie","family":"Liang","sequence":"additional","affiliation":[{"name":"Southwest Hospital","place":["Chongqing, P. R. China"]},{"name":"Third Military Medical University (Army Medical University)","place":["Chongqing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Medical Center, Peking Union Medical College Hospital","place":["Beijing, China"]},{"name":"Chinese Academy of Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Zhou","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Ying","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guichao","family":"Li","sequence":"additional","affiliation":[{"name":"Fudan University Shanghai Cancer Center","place":["Shanghai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4646-4391","authenticated-orcid":false,"given":"Muyan","family":"Cai","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center, The State Key Laboratory of Oncology in South China","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Ji","sequence":"additional","affiliation":[{"name":"Xijing Hospital","place":["Xi'an, P. R. China"]},{"name":"Air Force Military Medical University","place":["Xi'an, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiyuan","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanchang University","place":["Nanchang, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Hospital of Jilin University","place":["Changchun, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanguang","family":"Hu","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital","place":["Hangzhou, P. R. China"]},{"name":"Zhejiang University School of Medicine","place":["Hangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejun","family":"Nan","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Xi'an Jiaotong University","place":["Xi'an, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuhong","family":"Wang","sequence":"additional","affiliation":[{"name":"Second Affiliated Hospital","place":["Hangzhou, P. R. China"]},{"name":"Zhejiang University School of Medicine","place":["Hangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzhan","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital","place":["Hangzhou, P. R. China"]},{"name":"Zhejiang University School of Medicine","place":["Hangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai GoBroad Cancer Hospital","place":["Shanghai, P. R. China"]},{"name":"China Pharmaceutical University","place":["Shanghai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-8534","authenticated-orcid":false,"given":"Rui\u2010Hua","family":"Xu","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat\u2010sen University, Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"issue":"1","key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12885-018-5191-y","article-title":"Effects of subitems in the colorectal cancer screening protocol on the Chinese colorectal cancer screening program: an analysis based on natural community screening results","volume":"19","author":"Cai SR","year":"2019","unstructured":"Cai SR, Huang YQ, Zhang SZ, Li QR, Ma XY, Zheng S. Effects of subitems in the colorectal cancer screening protocol on the Chinese colorectal cancer screening program: an analysis based on natural community screening results. BMC Cancer. 2019;19((1)):47.","journal-title":"BMC Cancer"},{"issue":"8","key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.14309\/ajg.0000000000000624","article-title":"Comparative Evaluation of Participation and Diagnostic Yield of Colonoscopy vs Fecal Immunochemical Test vs Risk\u2010Adapted Screening in Colorectal Cancer Screening: Interim Analysis of a Multicenter Randomized Controlled Trial (TARGET\u2010C)","volume":"115","author":"Chen H","year":"2020","unstructured":"Chen H, Lu M, Liu C, Zou S, Du L, Liao X, et\u00a0al. Comparative Evaluation of Participation and Diagnostic Yield of Colonoscopy vs Fecal Immunochemical Test vs Risk\u2010Adapted Screening in Colorectal Cancer Screening: Interim Analysis of a Multicenter Randomized Controlled Trial (TARGET\u2010C). Am J Gastroenterol. 2020;115((8)):1264\u201374.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"e_1_3_2_4_2","first-page":"154","article-title":"[Age\u2010specific detection rates of colorectal neoplasms by colonoscopic screening in high\u2010incidence rural area]","volume":"35","author":"Li QL","year":"2013","unstructured":"Li QL, Ma XY, Yu LL, Xue F, Ma WL, Yao KY. [Age\u2010specific detection rates of colorectal neoplasms by colonoscopic screening in high\u2010incidence rural area]. Zhonghua Zhong Liu Za Zhi. 2013;35((2)):154\u20137.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"1","key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/gutjnl-2013-306503","article-title":"An updated Asia Pacific Consensus Recommendations on colorectal cancer screening","volume":"64","author":"Sung JJ","year":"2015","unstructured":"Sung JJ, Ng SC, Chan FK, Chiu HM, Kim HS, Matsuda T, et\u00a0al. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut. 2015;64((1)):121\u201332.","journal-title":"Gut"},{"issue":"3","key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.cgh.2013.08.042","article-title":"Development and validation of a scoring system to identify individuals at high risk for advanced colorectal neoplasms who should undergo colonoscopy screening","volume":"12","author":"Tao S","year":"2014","unstructured":"Tao S, Hoffmeister M, Brenner H. Development and validation of a scoring system to identify individuals at high risk for advanced colorectal neoplasms who should undergo colonoscopy screening. Clin Gastroenterol Hepatol. 2014;12((3)):478\u201385.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/CEJ.0b013e328364f229","article-title":"Predictive power of quantitative and qualitative fecal immunochemical tests for hemoglobin in population screening for colorectal neoplasm","volume":"23","author":"Huang Y","year":"2014","unstructured":"Huang Y, Li Q, Ge W, Cai S, Zhang S, Zheng S. Predictive power of quantitative and qualitative fecal immunochemical tests for hemoglobin in population screening for colorectal neoplasm. Eur J Cancer Prev. 2014;23((1)):27\u201334.","journal-title":"Eur J Cancer Prev"},{"issue":"3","key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.7326\/M13-1484","article-title":"Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta\u2010analysis","volume":"160","author":"Lee JK","year":"2014","unstructured":"Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta\u2010analysis. Ann Intern Med. 2014;160((3)):171.","journal-title":"Ann Intern Med"},{"key":"e_1_3_2_9_2","article-title":"Cost\u2010Effectiveness between Double and Single Fecal Immunochemical Test(s) in a Mass Colorectal Cancer Screening","volume":"2016","author":"Cai SR","year":"2016","unstructured":"Cai SR, Zhu HH, Huang YQ, Li QL, Ma XY, Zhang SZ, et\u00a0al. Cost\u2010Effectiveness between Double and Single Fecal Immunochemical Test(s) in a Mass Colorectal Cancer Screening. Biomed Res Int. 2016;2016:6830713.","journal-title":"Biomed Res Int"},{"issue":"01","key":"e_1_3_2_10_2","first-page":"1","article-title":"China guideline for the screening, early detection and early treatment of colorectal cancer (2020, Beijing)","volume":"30","author":"Chen WQ","year":"2021","unstructured":"Chen WQ, Li N, Lan P, Chen HD, Du LB, Sun F, et\u00a0al. China guideline for the screening, early detection and early treatment of colorectal cancer (2020, Beijing). China Cancer. 2021;30((01)):1\u201328.","journal-title":"China Cancer"},{"issue":"22","key":"e_1_3_2_11_2","first-page":"1691","article-title":"Expert consensus on early diagnosis and treatment of colorectal cancer in China","volume":"100","author":"Early Diagnosis and Early Treatment Group of the Oncology Branch of the Chinese Medical Association (CMA)","year":"2020","unstructured":"Early Diagnosis and Early Treatment Group of the Oncology Branch of the Chinese Medical Association (CMA) . Expert consensus on early diagnosis and treatment of colorectal cancer in China. Chin Med J (Engl). 2020;100((22)):1691\u20138.","journal-title":"Chin Med J (Engl)"},{"issue":"10","key":"e_1_3_2_12_2","first-page":"709","article-title":"Expert consensus opinion on early colorectal cancer screening process in China (2019, Shanghai)","volume":"36","author":"National Clinical Research Center for Digestive Diseases","year":"2019","unstructured":"National Clinical Research Center for Digestive Diseases , National Alliance for Early Diagnosis and Treatment of Digestive Tract Cancers , Digestive Endoscopy Society of Chinese Medical Association , Health Management Society of Chinese Medical Association , Digestive Endoscopy Professional Committee of the Endoscopy Physicians Branch of Chinese Medical Doctor Association , Endoscopic Health Management and Physical Examination Professional Committee of the Endoscopy Physicians Branch of Chinese Medical Doctor Association , et\u00a0al. Expert consensus opinion on early colorectal cancer screening process in China (2019, Shanghai). Chin J Dig Endosc. 2019;36((10)):709\u201319.","journal-title":"Chin J Dig Endosc"},{"issue":"10","key":"e_1_3_2_13_2","first-page":"1081","article-title":"Expert consensus on early diagnosis and screening strategies for colorectal tumours in China","volume":"21","author":"Colorectal Cancer Professional Committee of the Chinese Anti\u2010Cancer Association, Expert Committee for Consensus on Early Diagnosis and Screening for Colorectal Cancer in China","year":"2018","unstructured":"Colorectal Cancer Professional Committee of the Chinese Anti\u2010Cancer Association, Expert Committee for Consensus on Early Diagnosis and Screening for Colorectal Cancer in China . Expert consensus on early diagnosis and screening strategies for colorectal tumours in China. Chin J Gastrointest Surg. 2018;21((10)):1081\u20136.","journal-title":"Chin J Gastrointest Surg"},{"issue":"11","key":"e_1_3_2_14_2","first-page":"979","article-title":"Consensus opinion on colorectal tumour screening, early diagnosis and treatment and comprehensive prevention in China","volume":"20","author":"Chinese Society Of Gastroenterology","year":"2011","unstructured":"Chinese Society Of Gastroenterology . Consensus opinion on colorectal tumour screening, early diagnosis and treatment and comprehensive prevention in China. J Gastroenterol Hepatol. 2011;20((11)):979\u201395.","journal-title":"J Gastroenterol Hepatol"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311194"},{"issue":"23","key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1001\/jama.2016.3332","article-title":"Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force","volume":"315","author":"Lin JS","year":"2016","unstructured":"Lin JS, Piper MA, Perdue LA, Rutter CM, Webber EM, O'Connor E, et\u00a0al. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016;315((23)):2576\u201394.","journal-title":"JAMA"},{"issue":"4","key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2019.10.026","article-title":"Recommendations for Follow\u2010Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi\u2010Society Task Force on Colorectal Cancer","volume":"158","author":"Gupta S","year":"2020","unstructured":"Gupta S, Lieberman D, Anderson JC, Burke CA, Dominitz JA, Kaltenbach T, et\u00a0al. Recommendations for Follow\u2010Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi\u2010Society Task Force on Colorectal Cancer. Gastroenterology. 2020;158((4)):1131\u201353 e5.","journal-title":"Gastroenterology"},{"issue":"8","key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.cgh.2016.03.017","article-title":"Factors Associated With Recurrence of Advanced Colorectal Adenoma After Endoscopic Resection","volume":"14","author":"Facciorusso A","year":"2016","unstructured":"Facciorusso A, Di Maso M, Serviddio G, Vendemiale G, Spada C, Costamagna G, et\u00a0al. Factors Associated With Recurrence of Advanced Colorectal Adenoma After Endoscopic Resection. Clin Gastroenterol Hepatol. 2016;14((8)):1148\u201354 e4.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1055\/s-0042-112571","article-title":"Incidence of advanced neoplasia during surveillance in high\u2010 and intermediate\u2010risk groups of the European colorectal cancer screening guidelines","volume":"48","author":"Cubiella J","year":"2016","unstructured":"Cubiella J, Carballo F, Portillo I, Cruzado Quevedo J, Salas D, Binefa G, et\u00a0al. Incidence of advanced neoplasia during surveillance in high\u2010 and intermediate\u2010risk groups of the European colorectal cancer screening guidelines. Endoscopy. 2016;48((11)):995\u20131002.","journal-title":"Endoscopy"},{"issue":"1","key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13045-019-0702-0","article-title":"Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)","volume":"12","author":"Li J","year":"2019","unstructured":"Li J, Yuan Y, Yang F, Wang Y, Zhu X, Wang Z, et\u00a0al. Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition). J Hematol Oncol. 2019;12((1)):16.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1007\/s00330-019-06524-x","article-title":"Diagnostic performance of imaging for the detection of peritoneal metastases: a meta\u2010analysis","volume":"30","author":"van \u2019t Sant I","year":"2020","unstructured":"van \u2019t Sant I, Engbersen MP, Bhairosing PA, Lambregts DMJ, Beets\u2010Tan RGH, van Driel WJ, et\u00a0al. Diagnostic performance of imaging for the detection of peritoneal metastases: a meta\u2010analysis. Eur Radiol. 2020;30((6)):3101\u201312.","journal-title":"Eur Radiol"},{"issue":"3","key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/0284185120925481","article-title":"Imaging of colorectal cancer liver metastases using contrast\u2010enhanced US, multidetector CT, MRI, and FDG PET\/CT: a meta\u2010analysis","volume":"62","author":"Tsili AC","year":"2021","unstructured":"Tsili AC, Alexiou G, Naka C, Argyropoulou MI. Imaging of colorectal cancer liver metastases using contrast\u2010enhanced US, multidetector CT, MRI, and FDG PET\/CT: a meta\u2010analysis. Acta Radiol. 2021;62((3)):302\u201312.","journal-title":"Acta Radiol"},{"issue":"11","key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"6805","DOI":"10.1245\/s10434-021-09824-z","article-title":"When is a Ghost Really Gone? A Systematic Review and Meta\u2010analysis of the Accuracy of Imaging Modalities to Predict Complete Pathological Response of Colorectal Cancer Liver Metastases After Chemotherapy","volume":"28","author":"Muaddi H","year":"2021","unstructured":"Muaddi H, Silva S, Choi WJ, Coburn N, Hallet J, Law C, et\u00a0al. When is a Ghost Really Gone? A Systematic Review and Meta\u2010analysis of the Accuracy of Imaging Modalities to Predict Complete Pathological Response of Colorectal Cancer Liver Metastases After Chemotherapy. Ann Surg Oncol. 2021;28((11)):6805\u201313.","journal-title":"Ann Surg Oncol"},{"issue":"18","key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/jama.2014.3740","article-title":"Effect of PET Before Liver Resection on Surgical Management for Colorectal Adenocarcinoma Metastases: A Randomized Clinical Trial","volume":"311","author":"Moulton C\u2010A","year":"2014","unstructured":"Moulton C\u2010A, Gu C\u2010S, Law CH, Tandan VR, Hart R, Quan D, et\u00a0al. Effect of PET Before Liver Resection on Surgical Management for Colorectal Adenocarcinoma Metastases: A Randomized Clinical Trial. JAMA. 2014;311((18)):1863\u20139.","journal-title":"JAMA"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2022.101739"},{"issue":"9","key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/codi.15015","article-title":"The utility of preoperative radiological evaluation of early rectal neoplasia: a systematic review and meta\u2010analysis","volume":"22","author":"O'Connell E","year":"2020","unstructured":"O'Connell E, Galvin R, McNamara DA, Burke JP. The utility of preoperative radiological evaluation of early rectal neoplasia: a systematic review and meta\u2010analysis. Colorectal Dis. 2020;22((9)):1076\u201384.","journal-title":"Colorectal Dis"},{"issue":"5","key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/SLA.0000000000003516","article-title":"Predictive Factors and Risk Model for Positive Circumferential Resection Margin Rate After Transanal Total Mesorectal Excision in 2653 Patients With Rectal Cancer","volume":"270","author":"Roodbeen SX","year":"2019","unstructured":"Roodbeen SX, de Lacy FB, van Dieren S, Penna M, Ris F, Moran B, et\u00a0al. Predictive Factors and Risk Model for Positive Circumferential Resection Margin Rate After Transanal Total Mesorectal Excision in 2653 Patients With Rectal Cancer. Ann Surg. 2019;270((5)):884\u201391.","journal-title":"Ann Surg"},{"issue":"7","key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1007\/s00330-022-08591-z","article-title":"Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus","volume":"32","author":"Lambregts DMJ","year":"2022","unstructured":"Lambregts DMJ, Bogveradze N, Blomqvist LK, Fokas E, Garcia\u2010Aguilar J, Glimelius B, et\u00a0al. Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus. Eur Radiol. 2022;32((7)):4991\u20135003.","journal-title":"Eur Radiol"},{"issue":"7","key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1245\/s10434-011-2210-5","article-title":"Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta\u2010analysis","volume":"19","author":"Al\u2010Sukhni E","year":"2012","unstructured":"Al\u2010Sukhni E, Milot L, Fruitman M, Beyene J, Victor JC, Schmocker S, et\u00a0al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta\u2010analysis. Ann Surg Oncol. 2012;19((7)):2212\u201323.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"e_1_3_2_30_2","first-page":"1","article-title":"Chinese expert consensus on the diagnosis and treatment for lateral lymph node metastasis of rectal cancer (2024 edition)","volume":"27","author":"Laparoscopic Surgery Committee of the Endoscopist Branch in the Chinese Medical Doctor Association (CMDA)","year":"2024","unstructured":"Laparoscopic Surgery Committee of the Endoscopist Branch in the Chinese Medical Doctor Association (CMDA) , Laparoscopic Surgery Committee of Colorectal Cancer Committee of Chinese Medical Doctor Association (CMDA) , Colorectal Surgery Group of the Surgery Branch in the Chinese Medical Association (CMA) , Chinese Anti\u2010Cancer Association Colorectal Tumor Integrated Rehabilitation Committee , China International Exchange and Promotive Association for Medical and Health Care Colorectal Disease Branch , Zhou Zongguang , et\u00a0al. Chinese expert consensus on the diagnosis and treatment for lateral lymph node metastasis of rectal cancer (2024 edition). Chin J Gastrointest Surg. 2024;27((1)):1\u201314.","journal-title":"Chin J Gastrointest Surg"},{"issue":"12","key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1097\/DCR.0000000000002537","article-title":"The Role of Preoperative Imaging in the Detection of Lateral Lymph Node Metastases in Rectal Cancer: A Systematic Review and Diagnostic Test Meta\u2010analysis","volume":"65","author":"Rooney S","year":"2022","unstructured":"Rooney S, Meyer J, Afzal Z, Ashcroft J, Cheow H, De Paepe KN, et\u00a0al. The Role of Preoperative Imaging in the Detection of Lateral Lymph Node Metastases in Rectal Cancer: A Systematic Review and Diagnostic Test Meta\u2010analysis. Dis Colon Rectum. 2022;65((12)):1436\u201346.","journal-title":"Dis Colon Rectum"},{"issue":"2","key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/SLA.0000000000004636","article-title":"Oncologic Outcomes Associated With MRI\u2010detected Extramural Venous Invasion (mrEMVI) in Rectal Cancer: A Systematic Review and Meta\u2010analysis","volume":"275","author":"Rouleau Fournier F","year":"2022","unstructured":"Rouleau Fournier F, Motamedi MAK, Brown CJ, Phang T, Raval MJ, Hague CJ, et\u00a0al. Oncologic Outcomes Associated With MRI\u2010detected Extramural Venous Invasion (mrEMVI) in Rectal Cancer: A Systematic Review and Meta\u2010analysis. Ann Surg. 2022;275((2)):303\u201314.","journal-title":"Ann Surg"},{"issue":"7","key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"874","DOI":"10.6004\/jnccn.2018.0061","article-title":"Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Benson AB","year":"2018","unstructured":"Benson AB, Venook AP, Al\u2010Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et\u00a0al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16((7)):874\u2013901.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","article-title":"Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer","volume":"25","author":"Hashiguchi Y","year":"2020","unstructured":"Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et\u00a0al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25((1)):1\u201342.","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1470-2045(22)00214-5","article-title":"Assessment of the 2020 NICE criteria for preoperative radiotherapy in patients with rectal cancer treated by surgery alone in comparison with proven MRI prognostic factors: a retrospective cohort study","volume":"23","author":"Lord AC","year":"2022","unstructured":"Lord AC, Corr A, Chandramohan A, Hodges N, Pring E, Airo\u2010Farulla C, et\u00a0al. Assessment of the 2020 NICE criteria for preoperative radiotherapy in patients with rectal cancer treated by surgery alone in comparison with proven MRI prognostic factors: a retrospective cohort study. Lancet Oncol. 2022;23((6)):793\u2013801.","journal-title":"Lancet Oncol"},{"issue":"4","key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/SLA.0000000000001193","article-title":"Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification Model: The MERCURY II Study","volume":"263","author":"Battersby NJ","year":"2016","unstructured":"Battersby NJ, How P, Moran B, Stelzner S, West NP, Branagan G, et\u00a0al. Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification Model: The MERCURY II Study. Ann Surg. 2016;263((4)):751\u201360.","journal-title":"Ann Surg"},{"issue":"3","key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s00261-020-02770-6","article-title":"Comparison of percentage changes in quantitative diffusion parameters for assessing pathological complete response to neoadjuvant therapy in locally advanced rectal cancer: a meta\u2010analysis","volume":"46","author":"Chen K","year":"2021","unstructured":"Chen K, She HL, Wu T, Hu F, Li T, Luo LP. Comparison of percentage changes in quantitative diffusion parameters for assessing pathological complete response to neoadjuvant therapy in locally advanced rectal cancer: a meta\u2010analysis. Abdom Radiol (NY). 2021;46((3)):894\u2013908.","journal-title":"Abdom Radiol (NY)"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(21)00215-6"},{"issue":"1","key":"e_1_3_2_39_2","first-page":"13","article-title":"Optimal Interval to Surgery After Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Systematic Review and Meta\u2010analysis","volume":"17","author":"Du D","year":"2018","unstructured":"Du D, Su Z, Wang D, Liu W, Wei Z. Optimal Interval to Surgery After Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Systematic Review and Meta\u2010analysis. Clin Colorectal Cancer. 2018;17((1)):13\u201324.","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"e_1_3_2_40_2","first-page":"10","article-title":"MRI for Rectal Cancer: Staging, mrCRM, EMVI, Lymph Node Staging and Post\u2010Treatment Response","volume":"21","author":"Bates DDB","year":"2022","unstructured":"Bates DDB, Homsi ME, Chang KJ, Lalwani N, Horvat N, Sheedy SP. MRI for Rectal Cancer: Staging, mrCRM, EMVI, Lymph Node Staging and Post\u2010Treatment Response. Clin Colorectal Cancer. 2022;21((1)):10\u20138.","journal-title":"Clin Colorectal Cancer"},{"issue":"12","key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"8827","DOI":"10.1007\/s00330-021-07981-z","article-title":"The prognostic value of MRI\u2010detected extramural vascular invasion (mrEMVI) for rectal cancer patients treated with neoadjuvant therapy: a meta\u2010analysis","volume":"31","author":"Chen S","year":"2021","unstructured":"Chen S, Li N, Tang Y, Shi J, Zhao Y, Ma H, et\u00a0al. The prognostic value of MRI\u2010detected extramural vascular invasion (mrEMVI) for rectal cancer patients treated with neoadjuvant therapy: a meta\u2010analysis. Eur Radiol. 2021;31((12)):8827\u201337.","journal-title":"Eur Radiol"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201445"},{"issue":"6","key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cdip.2007.06.002","article-title":"Pathology of the endoscopically removed malignant colorectal polyp","volume":"13","author":"Cooper HS","year":"2007","unstructured":"Cooper HS. Pathology of the endoscopically removed malignant colorectal polyp. Current Diagnostic Pathol. 2007;13((6)):423\u201337.","journal-title":"Current Diagnostic Pathol"},{"issue":"3","key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.prp.2017.12.019","article-title":"Tumor budding and poorly\u2010differentiated cluster in prognostication in Stage II colon cancer","volume":"214","author":"Lee VWK","year":"2018","unstructured":"Lee VWK, Chan KF. Tumor budding and poorly\u2010differentiated cluster in prognostication in Stage II colon cancer. Pathol Res Pract. 2018;214((3)):402\u20137.","journal-title":"Pathol Res Pract"},{"issue":"5","key":"e_1_3_2_45_2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00384-019-03279-1","article-title":"Study of histopathologic parameters to define the prognosis of stage II colon cancer","volume":"34","author":"Romiti A","year":"2019","unstructured":"Romiti A, Roberto M, Marchetti P, Di Cerbo A, Falcone R, Campisi G, et\u00a0al. Study of histopathologic parameters to define the prognosis of stage II colon cancer. Int J Colorectal Dis. 2019;34((5)):905\u201313.","journal-title":"Int J Colorectal Dis"},{"key":"e_1_3_2_46_2","first-page":"1","article-title":"Treatment of Patients With Early\u2010Stage Colorectal Cancer: ASCO Resource\u2010Stratified Guideline","volume":"5","author":"Costas\u2010Chavarri A","year":"2019","unstructured":"Costas\u2010Chavarri A, Nandakumar G, Temin S, Lopes G, Cervantes A, Cruz Correa M, et\u00a0al. Treatment of Patients With Early\u2010Stage Colorectal Cancer: ASCO Resource\u2010Stratified Guideline. J Glob Oncol. 2019;5:1\u201319.","journal-title":"J Glob Oncol"},{"issue":"1","key":"e_1_3_2_47_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/modpathol.2016.166","article-title":"Colorectal carcinomas with submucosal invasion (pT1): analysis of histopathological and molecular factors predicting lymph node metastasis","volume":"30","author":"Pai RK","year":"2017","unstructured":"Pai RK, Cheng YW, Jakubowski MA, Shadrach BL, Plesec TP, Pai RK. Colorectal carcinomas with submucosal invasion (pT1): analysis of histopathological and molecular factors predicting lymph node metastasis. Mod Pathol. 2017;30((1)):113\u201322.","journal-title":"Mod Pathol"},{"issue":"9","key":"e_1_3_2_48_2","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/modpathol.2017.46","article-title":"Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016","volume":"30","author":"Lugli A","year":"2017","unstructured":"Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, et\u00a0al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30((9)):1299\u2013311.","journal-title":"Mod Pathol"},{"issue":"10","key":"e_1_3_2_49_2","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.6004\/jnccn.2022.0051","article-title":"Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Benson AB","year":"2022","unstructured":"Benson AB, Venook AP, Al\u2010Hawary MM, Azad N, Chen Y\u2010J, Ciombor KK, et\u00a0al. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2022;20((10)):1139\u201367.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"8","key":"e_1_3_2_50_2","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/jcp.2006.043802","article-title":"The total mesorectal excision specimen for rectal cancer: a review of its pathological assessment","volume":"60","author":"Parfitt JR","year":"2007","unstructured":"Parfitt JR, Driman DK. The total mesorectal excision specimen for rectal cancer: a review of its pathological assessment. J Clin Pathol. 2007;60((8)):849\u201355.","journal-title":"J Clin Pathol"},{"key":"e_1_3_2_51_2","volume-title":"WHO Classification of Tumours: Digestive System Tumours","author":"WHO Classification of Tumours Editorial Board","year":"2019","unstructured":"WHO Classification of Tumours Editorial Board . WHO Classification of Tumours: Digestive System Tumours. 5th ed. 2019.","edition":"5"},{"issue":"3","key":"e_1_3_2_52_2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00000478-200203000-00009","article-title":"Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit","volume":"26","author":"Nagtegaal ID","year":"2002","unstructured":"Nagtegaal ID, Marijnen CAM, Kranenbarg EK, van de Velde CJH, van Krieken JHJM, Pathology Review C, et\u00a0al. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol. 2002;26((3)):350\u20137.","journal-title":"Am J Surg Pathol"},{"key":"e_1_3_2_53_2","first-page":"1032","volume-title":"AJCC Cancer Staging Manual","author":"Amin MB","year":"2016","unstructured":"Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et\u00a0al. AJCC Cancer Staging Manual. 8 ed: Springer Cham; 2016;XVII:1032.","edition":"8"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.9807"},{"issue":"30","key":"e_1_3_2_55_2","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2018.78.3183","article-title":"Efficacy and Tolerability of First\u2010Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX\u20104) Versus FOLFOX\u20104 in Patients With RAS Wild\u2010Type Metastatic Colorectal Cancer: The Open\u2010Label, Randomized, Phase III TAILOR Trial","volume":"36","author":"Qin S","year":"2018","unstructured":"Qin S, Li J, Wang L, Xu J, Cheng Y, Bai Y, et\u00a0al. Efficacy and Tolerability of First\u2010Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX\u20104) Versus FOLFOX\u20104 in Patients With RAS Wild\u2010Type Metastatic Colorectal Cancer: The Open\u2010Label, Randomized, Phase III TAILOR Trial. J Clin Oncol. 2018;36((30)):3031\u20139.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908075"},{"issue":"6","key":"e_1_3_2_57_2","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/ijc.32489","article-title":"Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single\u2010center retrospective study of 1,834 Chinese patients with Stage I\u2010IV colorectal cancer","volume":"145","author":"Guo TA","year":"2019","unstructured":"Guo TA, Wu YC, Tan C, Jin YT, Sheng WQ, Cai SJ, et\u00a0al. Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single\u2010center retrospective study of 1,834 Chinese patients with Stage I\u2010IV colorectal cancer. Int J Cancer. 2019;145((6)):1625\u201334.","journal-title":"Int J Cancer"},{"issue":"1","key":"e_1_3_2_58_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2014.09.041","article-title":"Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes","volume":"148","author":"Sinicrope FA","year":"2015","unstructured":"Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, et\u00a0al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 2015;148((1)):88\u201399.","journal-title":"Gastroenterology"},{"issue":"23","key":"e_1_3_2_59_2","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.1158\/1078-0432.CCR-12-0605","article-title":"Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value","volume":"18","author":"Gavin PG","year":"2012","unstructured":"Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY, Yothers G, et\u00a0al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012;18((23)):6531\u201341.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"e_1_3_2_60_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Benson AB","year":"2021","unstructured":"Benson AB, Venook AP, Al\u2010Hawary MM, Arain MA, Chen Y\u2010J, Ciombor KK, et\u00a0al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2021;19((3)):329\u201359.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"e_1_3_2_61_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li MM","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et\u00a0al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19((1)):4\u201323.","journal-title":"J Mol Diagn"},{"issue":"4","key":"e_1_3_2_62_2","first-page":"237","article-title":"Expert consensus on molecular testing for colorectal cancer","volume":"47","author":"Panel Members of Expert Consensus on Molecular Testing for Colorectal Cancer","year":"2018","unstructured":"Panel Members of Expert Consensus on Molecular Testing for Colorectal Cancer . Expert consensus on molecular testing for colorectal cancer. Chinese Journal of Pathology. 2018;47((4)):237\u201340.","journal-title":"Chinese Journal of Pathology"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00150-9"},{"issue":"11","key":"e_1_3_2_64_2","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/PAS.0000000000000911","article-title":"Pan\u2010Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions","volume":"41","author":"Hechtman JF","year":"2017","unstructured":"Hechtman JF, Benayed R, Hyman DM, Drilon A, Zehir A, Frosina D, et\u00a0al. Pan\u2010Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. Am J Surg Pathol. 2017;41((11)):1547\u201351.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"e_1_3_2_65_2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","article-title":"NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls","volume":"33","author":"Solomon JP","year":"2020","unstructured":"Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, et\u00a0al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33((1)):38\u201346.","journal-title":"Mod Pathol"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/his.13984"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01108-w"},{"issue":"6","key":"e_1_3_2_68_2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006658","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer","volume":"11","author":"Kelly RJ","year":"2023","unstructured":"Kelly RJ, Bever K, Chao J, Ciombor KK, Eng C, Fakih M, et\u00a0al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer. J Immunother Cancer. 2023;11((6)).","journal-title":"J Immunother Cancer"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0528"},{"issue":"1","key":"e_1_3_2_70_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-021-01089-z","article-title":"Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer","volume":"14","author":"Chen G","year":"2021","unstructured":"Chen G, Peng J, Xiao Q, Wu HX, Wu X, Wang F, et\u00a0al. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. J Hematol Oncol. 2021;14((1)):80.","journal-title":"J Hematol Oncol"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2404"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200075"},{"issue":"3","key":"e_1_3_2_73_2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.gie.2014.07.034","article-title":"Efficacy and adverse events of EMR and endoscopic submucosal dissection for the treatment of colon neoplasms: a meta\u2010analysis of studies comparing EMR and endoscopic submucosal dissection","volume":"81","author":"Fujiya M","year":"2015","unstructured":"Fujiya M, Tanaka K, Dokoshi T, Tominaga M, Ueno N, Inaba Y, et\u00a0al. Efficacy and adverse events of EMR and endoscopic submucosal dissection for the treatment of colon neoplasms: a meta\u2010analysis of studies comparing EMR and endoscopic submucosal dissection. Gastrointest Endosc. 2015;81((3)):583\u201395.","journal-title":"Gastrointest Endosc"},{"key":"e_1_3_2_74_2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.critrevonc.2016.06.008","article-title":"Endoscopic mucosal resection and endoscopic submucosal dissection for colorectal lesions: A systematic review","volume":"104","author":"De Ceglie A","year":"2016","unstructured":"De Ceglie A, Hassan C, Mangiavillano B, Matsuda T, Saito Y, Ridola L, et\u00a0al. Endoscopic mucosal resection and endoscopic submucosal dissection for colorectal lesions: A systematic review. Crit Rev Oncol Hematol. 2016;104:138\u201355.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"e_1_3_2_75_2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-0043-102569","article-title":"Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline","volume":"49","author":"Ferlitsch M","year":"2017","unstructured":"Ferlitsch M, Moss A, Hassan C, Bhandari P, Dumonceau JM, Paspatis G, et\u00a0al. Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2017;49((3)):270\u201397.","journal-title":"Endoscopy"},{"issue":"7","key":"e_1_3_2_76_2","first-page":"445","article-title":"Endoscopic Treatment of Early Cancer of the Colon","volume":"11","author":"Ribeiro MS","year":"2015","unstructured":"Ribeiro MS, Wallace MB. Endoscopic Treatment of Early Cancer of the Colon. Gastroenterol Hepatol (N Y). 2015;11((7)):445\u201352.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"4","key":"e_1_3_2_77_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/den.12456","article-title":"JGES guidelines for colorectal endoscopic submucosal dissection\/endoscopic mucosal resection","volume":"27","author":"Tanaka S","year":"2015","unstructured":"Tanaka S, Kashida H, Saito Y, Yahagi N, Yamano H, Saito S, et\u00a0al. JGES guidelines for colorectal endoscopic submucosal dissection\/endoscopic mucosal resection. Dig Endosc. 2015;27((4)):417\u201334.","journal-title":"Dig Endosc"},{"issue":"1","key":"e_1_3_2_78_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-017-1101-6","article-title":"Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer","volume":"23","author":"Watanabe T","year":"2018","unstructured":"Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, et\u00a0al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23((1)):1\u201334.","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"e_1_3_2_79_2","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/0016-5085(95)90126-4","article-title":"Endoscopically removed malignant colorectal polyps: clinicopathologic correlations","volume":"108","author":"Cooper HS","year":"1995","unstructured":"Cooper HS, Deppisch LM, Gourley WK, Kahn EI, Lev R, Manley PN, et\u00a0al. Endoscopically removed malignant colorectal polyps: clinicopathologic correlations. Gastroenterology. 1995;108((6)):1657\u201365.","journal-title":"Gastroenterology"},{"issue":"2","key":"e_1_3_2_80_2","first-page":"93","article-title":"Management of colorectal polyps","volume":"47","author":"Markowitz AJ","year":"1997","unstructured":"Markowitz AJ, Winawer SJ. Management of colorectal polyps. CA Cancer J Clin. 1997;47((2)):93\u2013112.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"e_1_3_2_81_2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cgh.2013.08.008","article-title":"Factors associated with risk for colorectal cancer recurrence after endoscopic resection of T1 tumors","volume":"12","author":"Yoshii S","year":"2014","unstructured":"Yoshii S, Nojima M, Nosho K, Omori S, Kusumi T, Okuda H, et\u00a0al. Factors associated with risk for colorectal cancer recurrence after endoscopic resection of T1 tumors. Clin Gastroenterol Hepatol. 2014;12((2)):292\u2013302 e3.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"e_1_3_2_82_2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/00000478-198310000-00002","article-title":"Surgical pathology of endoscopically removed malignant polyps of the colon and rectum","volume":"7","author":"Cooper HS","year":"1983","unstructured":"Cooper HS. Surgical pathology of endoscopically removed malignant polyps of the colon and rectum. Am J Surg Pathol. 1983;7((7)):613\u201323.","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"e_1_3_2_83_2","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s10350-005-0063-3","article-title":"Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled\u2010data analysis","volume":"48","author":"Hassan C","year":"2005","unstructured":"Hassan C, Zullo A, Risio M, Rossini FP, Morini S. Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled\u2010data analysis. Dis Colon Rectum. 2005;48((8)):1588\u201396.","journal-title":"Dis Colon Rectum"},{"issue":"11","key":"e_1_3_2_84_2","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s10350-004-0680-2","article-title":"Is Endoscopic Polypectomy an Adequate Therapy for Malignant Colorectal Adenomas? Presentation of 114 Patients and Review of the Literature","volume":"47","author":"Seitz U","year":"2004","unstructured":"Seitz U, Bohnacker S, Seewald S, Thonke F, Brand B, Br\u00e4utigam T, et\u00a0al. Is Endoscopic Polypectomy an Adequate Therapy for Malignant Colorectal Adenomas? Presentation of 114 Patients and Review of the Literature. Diseases of the Colon & Rectum. 2004;47((11)):1789\u201397.","journal-title":"Diseases of the Colon & Rectum"},{"issue":"6","key":"e_1_3_2_85_2","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/0016-5085(95)90746-7","article-title":"Management and outcome of patients with invasive carcinoma arising in colorectal polyps","volume":"109","author":"Volk EE","year":"1995","unstructured":"Volk EE, Goldblum JR, Petras RE, Carey WD, Fazio VW. Management and outcome of patients with invasive carcinoma arising in colorectal polyps. Gastroenterology. 1995;109((6)):1801\u20137.","journal-title":"Gastroenterology"},{"issue":"2","key":"e_1_3_2_86_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0016-5085(86)90577-9","article-title":"When is endoscopic polypectomy adequate therapy for colonic polyps containing invasive carcinoma?","volume":"91","author":"Cranley JP","year":"1986","unstructured":"Cranley JP, Petras RE, Carey WD, Paradis K, Sivak MV. When is endoscopic polypectomy adequate therapy for colonic polyps containing invasive carcinoma? Gastroenterology. 1986;91((2)):419\u201327.","journal-title":"Gastroenterology"},{"issue":"2","key":"e_1_3_2_87_2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/0016-5085(85)90333-6","article-title":"Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy","volume":"89","author":"Haggitt RC","year":"1985","unstructured":"Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology. 1985;89((2)):328\u201336.","journal-title":"Gastroenterology"},{"issue":"1","key":"e_1_3_2_88_2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD\u20101 blockade with toripalimab, with or without celecoxib, in mismatch repair\u2010deficient or microsatellite instability\u2010high, locally advanced, colorectal cancer (PICC): a single\u2010centre, parallel\u2010group, non\u2010comparative, randomised, phase 2 trial","volume":"7","author":"Hu H","year":"2022","unstructured":"Hu H, Kang L, Zhang J, Wu Z, Wang H, Huang M, et\u00a0al. Neoadjuvant PD\u20101 blockade with toripalimab, with or without celecoxib, in mismatch repair\u2010deficient or microsatellite instability\u2010high, locally advanced, colorectal cancer (PICC): a single\u2010centre, parallel\u2010group, non\u2010comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7((1)):38\u201348.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"21","key":"e_1_3_2_89_2","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair\u2010Deficient Colon Cancer","volume":"390","author":"Chalabi M","year":"2024","unstructured":"Chalabi M, Verschoor YL, Tan PB, Balduzzi S, Van Lent AU, Grootscholten C, et\u00a0al. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair\u2010Deficient Colon Cancer. N Engl J Med. 2024;390((21)):1949\u201358.","journal-title":"N Engl J Med"},{"issue":"4","key":"e_1_3_2_90_2","first-page":"381","article-title":"Surgical considerations in patients with cancer of the colon and rectum","volume":"18","author":"Cohen AM","year":"1991","unstructured":"Cohen AM. Surgical considerations in patients with cancer of the colon and rectum. Semin Oncol. 1991;18((4)):381\u20137.","journal-title":"Semin Oncol"},{"issue":"2","key":"e_1_3_2_91_2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2009.24.1448","article-title":"Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon","volume":"28","author":"West NP","year":"2010","unstructured":"West NP, Hohenberger W, Weber K, Perrakis A, Finan PJ, Quirke P. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol. 2010;28((2)):272\u20138.","journal-title":"J Clin Oncol"},{"issue":"34","key":"e_1_3_2_92_2","doi-asserted-by":"crossref","first-page":"8706","DOI":"10.1200\/JCO.2005.02.8852","article-title":"Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes","volume":"23","author":"Berger AC","year":"2005","unstructured":"Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS, et\u00a0al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol. 2005;23((34)):8706\u201312.","journal-title":"J Clin Oncol"},{"issue":"3","key":"e_1_3_2_93_2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s11605-013-2344-9","article-title":"Preoperative colonic stents versus emergency surgery for acute left\u2010sided malignant colonic obstruction: a meta\u2010analysis","volume":"18","author":"Huang X","year":"2014","unstructured":"Huang X, Lv B, Zhang S, Meng L. Preoperative colonic stents versus emergency surgery for acute left\u2010sided malignant colonic obstruction: a meta\u2010analysis. J Gastrointest Surg. 2014;18((3)):584\u201391.","journal-title":"J Gastrointest Surg"},{"issue":"27","key":"e_1_3_2_94_2","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.2012.42.5645","article-title":"Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial","volume":"30","author":"Tournigand C","year":"2012","unstructured":"Tournigand C, Andr\u00e9 T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, et\u00a0al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol. 2012;30((27)):3353\u201360.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.1825"},{"issue":"13","key":"e_1_3_2_96_2","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of Adjuvant Chemotherapy for Stage III Colon Cancer","volume":"378","author":"Grothey A","year":"2018","unstructured":"Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et\u00a0al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med. 2018;378((13)):1177\u201388.","journal-title":"N Engl J Med"},{"issue":"15","key":"e_1_3_2_97_2","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.2019.37.15_suppl.3501","article-title":"Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin\u2010based therapy (3 vs 6 months {m}) for patients (pts) with high\u2010risk stage II colorectal cancer (CC)","volume":"37","author":"Iveson T","year":"2019","unstructured":"Iveson T, Sobrero AF, Yoshino T, Sougklakos I, Ou F\u2010S, Meyers JP, et\u00a0al. Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin\u2010based therapy (3 vs 6 months {m}) for patients (pts) with high\u2010risk stage II colorectal cancer (CC). J Clin Oncol. 2019;37((15)_suppl):3501\u2010.","journal-title":"J Clin Oncol"},{"issue":"3","key":"e_1_3_2_98_2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/1758834015572343","article-title":"Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review","volume":"7","author":"Chibaudel B","year":"2015","unstructured":"Chibaudel B, Tournigand C, Bonnetain F, Richa H, Benetkiewicz M, Andre T, et\u00a0al. Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. Ther Adv Med Oncol. 2015;7((3)):153\u201369.","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"e_1_3_2_99_2","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin\u2010based chemotherapy as first\u2010line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz LB","year":"2008","unstructured":"Saltz LB, Clarke S, D\u00edaz\u2010Rubio E, Scheithauer W, Figer A, Wong R, et\u00a0al. Bevacizumab in combination with oxaliplatin\u2010based chemotherapy as first\u2010line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26((12)):2013\u201319.","journal-title":"J Clin Oncol"},{"issue":"17","key":"e_1_3_2_100_2","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis F","year":"2014","unstructured":"Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et\u00a0al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371((17)):1609\u201318.","journal-title":"N Engl J Med"},{"issue":"19","key":"e_1_3_2_101_2","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1200\/JCO.2009.27.7723","article-title":"Capecitabine, bevacizumab, and mitomycin in first\u2010line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study","volume":"28","author":"Tebbutt NC","year":"2010","unstructured":"Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, et\u00a0al. Capecitabine, bevacizumab, and mitomycin in first\u2010line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol. 2010;28((19)):3191\u20138.","journal-title":"J Clin Oncol"},{"issue":"16","key":"e_1_3_2_102_2","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","article-title":"Addition of bevacizumab to bolus fluorouracil and leucovorin in first\u2010line metastatic colorectal cancer: results of a randomized phase II trial","volume":"23","author":"Kabbinavar FF","year":"2005","unstructured":"Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et\u00a0al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first\u2010line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23((16)):3697\u2013705.","journal-title":"J Clin Oncol"},{"issue":"5","key":"e_1_3_2_103_2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/JCO.2008.19.8135","article-title":"A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer","volume":"27","author":"Hecht JR","year":"2009","unstructured":"Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et\u00a0al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27((5)):672\u201380.","journal-title":"J Clin Oncol"},{"issue":"6","key":"e_1_3_2_104_2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa0808268","article-title":"Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer","volume":"360","author":"Tol J","year":"2009","unstructured":"Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et\u00a0al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360((6)):563\u201372.","journal-title":"N Engl J Med"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699"},{"issue":"1","key":"e_1_3_2_106_2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12885-021-07894-6","article-title":"Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: a potential improvement to overall survival and decrease to multivisceral resection","volume":"21","author":"Yuan Y","year":"2021","unstructured":"Yuan Y, Xiao W\u2010W, Xie W\u2010H, Cai P\u2010Q, Wang Q\u2010X, Chang H, et\u00a0al. Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: a potential improvement to overall survival and decrease to multivisceral resection. BMC Cancer. 2021;21((1)):179.","journal-title":"BMC Cancer"},{"issue":"3","key":"e_1_3_2_107_2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5946\/ce.2015.48.3.194","article-title":"Colorectal Stents: Current Status","volume":"48","author":"Lee JM","year":"2015","unstructured":"Lee JM, Byeon JS. Colorectal Stents: Current Status. Clin Endosc. 2015;48((3)):194\u2013200.","journal-title":"Clin Endosc"},{"issue":"1","key":"e_1_3_2_108_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4251\/wjgo.v8.i1.113","article-title":"Role of self expandable stents in management of colorectal cancers","volume":"8","author":"Cetinkaya E","year":"2016","unstructured":"Cetinkaya E, Dogrul AB, Tirnaksiz MB. Role of self expandable stents in management of colorectal cancers. World J Gastrointest Oncol. 2016;8((1)):113\u201320.","journal-title":"World J Gastrointest Oncol"},{"issue":"5","key":"e_1_3_2_109_2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ejso.2006.02.001","article-title":"Resection margin in patients undergoing hepatectomy for colorectal liver metastasis: a critical appraisal of the 1cm rule","volume":"32","author":"Hamady ZZ","year":"2006","unstructured":"Hamady ZZ, Cameron IC, Wyatt J, Prasad RK, Toogood GJ, Lodge JP. Resection margin in patients undergoing hepatectomy for colorectal liver metastasis: a critical appraisal of the 1cm rule. Eur J Surg Oncol. 2006;32((5)):557\u201363.","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"e_1_3_2_110_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases","volume":"230","author":"Fong Y","year":"1999","unstructured":"Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230((3)):309\u201318; discussion 18\u201021.","journal-title":"Ann Surg"},{"issue":"7","key":"e_1_3_2_111_2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.ejso.2015.04.012","article-title":"The use of neo\u2010adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator","volume":"41","author":"Ayez N","year":"2015","unstructured":"Ayez N, van der Stok EP, Grunhagen DJ, Rothbarth J, van Meerten E, Eggermont AM, et\u00a0al. The use of neo\u2010adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator. Eur J Surg Oncol. 2015;41((7)):859\u201367.","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"e_1_3_2_112_2","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1245\/s10434-021-10143-6","article-title":"A Prognostic Scoring System to Predict Survival Outcome of Resectable Colorectal Liver Metastases in this Modern Era","volume":"28","author":"Liu W","year":"2021","unstructured":"Liu W, Zhang W, Xu Y, Li YH, Xing BC. A Prognostic Scoring System to Predict Survival Outcome of Resectable Colorectal Liver Metastases in this Modern Era. Ann Surg Oncol. 2021;28((12)):7709\u201318.","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_2_113_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw235"},{"issue":"4","key":"e_1_3_2_114_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.eng.2020.10.017","article-title":"Temporal Change in Treatment Patterns of Metastatic Colorectal Cancer and Its Association with Patient Survival: A Retrospective Cohort Study Based on an Intelligent Big\u2010Data Platform","volume":"7","author":"Wang Z\u2010X","year":"2021","unstructured":"Wang Z\u2010X, Yao Y\u2010C, Mai Z\u2010J, Lin W\u2010H, Huang Y\u2010S, Jin Y, et\u00a0al. Temporal Change in Treatment Patterns of Metastatic Colorectal Cancer and Its Association with Patient Survival: A Retrospective Cohort Study Based on an Intelligent Big\u2010Data Platform. Engineering. 2021;7((4)):526\u201333.","journal-title":"Engineering"},{"issue":"2","key":"e_1_3_2_115_2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","article-title":"Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild\u2010Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE\u20103 Trials","volume":"3","author":"Tejpar S","year":"2017","unstructured":"Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, et\u00a0al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild\u2010Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE\u20103 Trials. JAMA Oncol. 2017;3((2)):194\u2013201.","journal-title":"JAMA Oncol"},{"issue":"7","key":"e_1_3_2_116_2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.6004\/jnccn.2018.7279","article-title":"Chemotherapy With or Without Anti\u2010EGFR Agents in Left\u2010 and Right\u2010Sided Metastatic Colorectal Cancer: An Updated Meta\u2010Analysis","volume":"17","author":"Wang ZX","year":"2019","unstructured":"Wang ZX, Wu HX, He MM, Wang YN, Luo HY, Ding PR, et\u00a0al. Chemotherapy With or Without Anti\u2010EGFR Agents in Left\u2010 and Right\u2010Sided Metastatic Colorectal Cancer: An Updated Meta\u2010Analysis. J Natl Compr Canc Netw. 2019;17((7)):805\u201311.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"e_1_3_2_117_2","article-title":"Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Benson AB","year":"2024","unstructured":"Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, et\u00a0al. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22((2 d)):e240029.","journal-title":"J Natl Compr Canc Netw"},{"key":"e_1_3_2_118_2","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1200\/JCO.2022.40.16_suppl.3510","article-title":"Nivolumab (NIVO) \u00b1 ipilimumab (IPI) in patients (pts) with microsatellite instability\u2010high\/mismatch repair\u2010deficient (MSI\u2010H\/dMMR) metastatic colorectal cancer (mCRC): Five\u2010year follow\u2010up from CheckMate 142","volume":"40","author":"Overman MJ","year":"2022","unstructured":"Overman MJ, Lenz H\u2010J, Andre T, Aglietta M, Wong MK, Luppi G, et\u00a0al. Nivolumab (NIVO) \u00b1 ipilimumab (IPI) in patients (pts) with microsatellite instability\u2010high\/mismatch repair\u2010deficient (MSI\u2010H\/dMMR) metastatic colorectal cancer (mCRC): Five\u2010year follow\u2010up from CheckMate 142. J Clin Oncol. 2022;40(16_suppl):3510\u2010.","journal-title":"J Clin Oncol"},{"issue":"4","key":"e_1_3_2_119_2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/annonc\/mdv012","article-title":"Continuation or reintroduction of bevacizumab beyond progression to first\u2010line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial","volume":"26","author":"Masi G","year":"2015","unstructured":"Masi G, Salvatore L, Boni L, Loupakis F, Cremolini C, Fornaro L, et\u00a0al. Continuation or reintroduction of bevacizumab beyond progression to first\u2010line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol. 2015;26((4)):724\u201330.","journal-title":"Ann Oncol"},{"key":"e_1_3_2_120_2","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2147\/DDDT.S80449","article-title":"A phase I\/II study of biweekly capecitabine and irinotecan plus bevacizumab as second\u2010line chemotherapy in patients with metastatic colorectal cancer","volume":"9","author":"Suenaga M","year":"2015","unstructured":"Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, et\u00a0al. A phase I\/II study of biweekly capecitabine and irinotecan plus bevacizumab as second\u2010line chemotherapy in patients with metastatic colorectal cancer. Drug Des Devel Ther. 2015;9:1653\u201362.","journal-title":"Drug Des Devel Ther."},{"issue":"5","key":"e_1_3_2_121_2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S1470-2045(18)30140-2","article-title":"Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second\u2010line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open\u2010label, randomised, non\u2010inferiority, phase 3 trial","volume":"19","author":"Xu RH","year":"2018","unstructured":"Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, et\u00a0al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second\u2010line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open\u2010label, randomised, non\u2010inferiority, phase 3 trial. Lancet Oncol. 2018;19((5)):660\u201371.","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_122_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01994"},{"issue":"6","key":"e_1_3_2_123_2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double\u2010blind, placebo\u2010controlled, phase 3 trial","volume":"16","author":"Li J","year":"2015","unstructured":"Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, et\u00a0al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double\u2010blind, placebo\u2010controlled, phase 3 trial. Lancet Oncol. 2015;16((6)):619\u201329.","journal-title":"Lancet Oncol"},{"issue":"4","key":"e_1_3_2_124_2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.2018.36.4_suppl.611","article-title":"Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC): An ACCRU Network study","volume":"36","author":"Bekaii\u2010Saab TS","year":"2018","unstructured":"Bekaii\u2010Saab TS, Ou F\u2010S, Anderson DM, Ahn DH, Boland PM, Ciombor KK, et\u00a0al. Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC): An ACCRU Network study. J Clin Oncol. 2018;36((4)_suppl):611.","journal-title":"J Clin Oncol"},{"issue":"24","key":"e_1_3_2_125_2","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial","volume":"319","author":"Li J","year":"2018","unstructured":"Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y, et\u00a0al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018;319((24)):2486\u201396.","journal-title":"JAMA"},{"issue":"4","key":"e_1_3_2_126_2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a Randomized, Double\u2010Blind, Placebo\u2010Controlled, Phase III Trial of Trifluridine\/Tipiracil (TAS\u2010102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study","volume":"36","author":"Xu J","year":"2018","unstructured":"Xu J, Kim TW, Shen L, Sriuranpong V, Pan H, Xu R, et\u00a0al. Results of a Randomized, Double\u2010Blind, Placebo\u2010Controlled, Phase III Trial of Trifluridine\/Tipiracil (TAS\u2010102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. J Clin Oncol. 2018;36((4)):350\u20138.","journal-title":"J Clin Oncol"},{"issue":"18","key":"e_1_3_2_127_2","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine\u2013Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer","volume":"388","author":"Prager GW","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, Ciardiello F, Cutsem EV, Elez E, et\u00a0al. Trifluridine\u2013Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med. 2023;388((18)):1657\u201367.","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_3_2_128_2","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","article-title":"Final results of DESTINY\u2010CRC01 investigating trastuzumab deruxtecan in patients with HER2\u2010expressing metastatic colorectal cancer","volume":"14","author":"Yoshino T","year":"2023","unstructured":"Yoshino T, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, et\u00a0al. Final results of DESTINY\u2010CRC01 investigating trastuzumab deruxtecan in patients with HER2\u2010expressing metastatic colorectal cancer. Nat Commun. 2023;14((1)):3332.","journal-title":"Nat Commun"},{"issue":"36","key":"e_1_3_2_129_2","doi-asserted-by":"crossref","first-page":"9243","DOI":"10.1200\/JCO.2005.07.740","article-title":"Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver\u2010only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study","volume":"23","author":"Alberts SR","year":"2005","unstructured":"Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, et\u00a0al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver\u2010only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23((36)):9243\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"e_1_3_2_130_2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(23)00219-X","article-title":"First\u2010line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open\u2010label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group","volume":"24","author":"Bond MJG","year":"2023","unstructured":"Bond MJG, Bolhuis K, Loosveld OJL, de Groot JWB, Droogendijk H, Helgason HH, et\u00a0al. First\u2010line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open\u2010label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. Lancet Oncol. 2023;24((7)):757\u201371.","journal-title":"Lancet Oncol"},{"issue":"6","key":"e_1_3_2_131_2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1159\/000355914","article-title":"Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III \u2018Stop and Go\u2019 study results\u2013a Turkish Oncology Group Trial","volume":"85","author":"Yalcin S","year":"2013","unstructured":"Yalcin S, Uslu R, Dane F, Yilmaz U, Zengin N, Buyukunal E, et\u00a0al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III \u2018Stop and Go\u2019 study results\u2013a Turkish Oncology Group Trial. Oncology. 2013;85((6)):328\u201335.","journal-title":"Oncology"},{"key":"e_1_3_2_132_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ctrv.2015.10.012","article-title":"Maintenance strategy in metastatic colorectal cancer: A systematic review","volume":"42","author":"Esin E","year":"2016","unstructured":"Esin E, Yalcin S. Maintenance strategy in metastatic colorectal cancer: A systematic review. Cancer Treat Rev. 2016;42:82\u201390.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"e_1_3_2_133_2","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1097\/SLA.0000000000001326","article-title":"Palliative Primary Tumor Resection in Patients With Metastatic Colorectal Cancer: For Whom and When?","volume":"265","author":"Tarantino I","year":"2017","unstructured":"Tarantino I, Warschkow R, Guller U. Palliative Primary Tumor Resection in Patients With Metastatic Colorectal Cancer: For Whom and When? Ann Surg. 2017;265((4)):e59\u2013e60.","journal-title":"Ann Surg"},{"issue":"3","key":"e_1_3_2_134_2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/jamasurg.2014.2253","article-title":"Time trend analysis of primary tumor resection for stage IV colorectal cancer: less surgery, improved survival","volume":"150","author":"Hu CY","year":"2015","unstructured":"Hu CY, Bailey CE, You YN, Skibber JM, Rodriguez\u2010Bigas MA, Feig BW, et\u00a0al. Time trend analysis of primary tumor resection for stage IV colorectal cancer: less surgery, improved survival. JAMA Surg. 2015;150((3)):245\u201351.","journal-title":"JAMA Surg"},{"issue":"1","key":"e_1_3_2_135_2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/jjco\/hyz173","article-title":"A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study)","volume":"50","author":"Moritani K","year":"2020","unstructured":"Moritani K, Kanemitsu Y, Shida D, Shitara K, Mizusawa J, Katayama H, et\u00a0al. A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study). Jpn J Clin Oncol. 2020;50((1)):89\u201393.","journal-title":"Jpn J Clin Oncol"},{"issue":"23","key":"e_1_3_2_136_2","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C","volume":"389","author":"Fakih MG","year":"2023","unstructured":"Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez\u2010Bravo DP, Taieb J, et\u00a0al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023;389((23)):2125\u201339.","journal-title":"N Engl J Med"},{"key":"e_1_3_2_137_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0521"},{"key":"e_1_3_2_138_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2963"},{"issue":"9","key":"e_1_3_2_139_2","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.524","article-title":"POLE\/POLD1 mutation in non\u2010exonuclease domain matters for predicting efficacy of immune\u2010checkpoint\u2010inhibitor therapy","volume":"11","author":"Chen YX","year":"2021","unstructured":"Chen YX, Wang ZX, Yuan SQ, Jiang TJ, Huang YS, Xu RH, et\u00a0al. POLE\/POLD1 mutation in non\u2010exonuclease domain matters for predicting efficacy of immune\u2010checkpoint\u2010inhibitor therapy. Clin Transl Med. 2021;11((9)):e524.","journal-title":"Clin Transl Med"},{"issue":"1","key":"e_1_3_2_140_2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-024-01939-5","article-title":"A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon\/polymerase delta (POLE\/POLD1) mutation","volume":"9","author":"Jin Y","year":"2024","unstructured":"Jin Y, Huang R\u2010J, Guan W\u2010L, Wang Z\u2010Q, Mai Z\u2010J, Li Y\u2010H, et\u00a0al. A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon\/polymerase delta (POLE\/POLD1) mutation. Signal Transduct Targ Ther. 2024;9((1)):227.","journal-title":"Signal Transduct Targ Ther"},{"issue":"18","key":"e_1_3_2_141_2","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open\u2010Label, Dose\u2010Escalation, and Dose\u2010Expansion Phase Ib Trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka S","year":"2020","unstructured":"Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, et\u00a0al. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open\u2010Label, Dose\u2010Escalation, and Dose\u2010Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol. 2020;38((18)):2053\u201361.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_142_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100383"},{"key":"e_1_3_2_143_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101917","article-title":"Regorafenib plus nivolumab in patients with mismatch repair\u2010proficient\/microsatellite stable metastatic colorectal cancer: a single\u2010arm, open\u2010label, multicentre phase 2 study","volume":"58","author":"Fakih M","year":"2023","unstructured":"Fakih M, Raghav KPS, Chang DZ, Larson T, Cohn AL, Huyck TK, et\u00a0al. Regorafenib plus nivolumab in patients with mismatch repair\u2010proficient\/microsatellite stable metastatic colorectal cancer: a single\u2010arm, open\u2010label, multicentre phase 2 study. EClinicalMedicine. 2023;58:101917.","journal-title":"EClinicalMedicine"},{"key":"e_1_3_2_144_2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejca.2022.12.004","article-title":"Phase 1b\/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose\u2010escalation and metastatic colorectal cancer cohort in the dose\u2010expansion phases","volume":"181","author":"Guo Y","year":"2023","unstructured":"Guo Y, Zhang W, Ying J, Zhang Y, Pan Y, Qiu W, et\u00a0al. Phase 1b\/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose\u2010escalation and metastatic colorectal cancer cohort in the dose\u2010expansion phases. Eur J Cancer. 2023;181:26\u201337.","journal-title":"Eur J Cancer"},{"key":"e_1_3_2_145_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02813-1"},{"issue":"9","key":"e_1_3_2_146_2","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.medj.2024.05.009","article-title":"First\u2010line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double\u2010blind, phase 2\/3 trial","volume":"5","author":"Wang ZX","year":"2024","unstructured":"Wang ZX, Peng J, Liang X, Cheng Y, Deng Y, Chen K, et\u00a0al. First\u2010line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double\u2010blind, phase 2\/3 trial. Med. 2024;5((9)):1150\u201363.e3.","journal-title":"Med"},{"key":"e_1_3_2_147_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102123","article-title":"Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first\u2010line therapy in RAS\u2010mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open\u2010label, single\u2010arm, phase II trial","volume":"62","author":"Fang X","year":"2023","unstructured":"Fang X, Zhu N, Zhong C, Wang L, Li J, Weng S, et\u00a0al. Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first\u2010line therapy in RAS\u2010mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open\u2010label, single\u2010arm, phase II trial. EClinicalMedicine. 2023;62:102123.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"e_1_3_2_148_2","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2006.03.013","article-title":"Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi\u2010Society Task Force on Colorectal Cancer","volume":"130","author":"Rex DK","year":"2006","unstructured":"Rex DK, Kahi CJ, Levin B, Smith RA, Bond JH, Brooks D, et\u00a0al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi\u2010Society Task Force on Colorectal Cancer. Gastroenterology. 2006;130((6)):1865\u201371.","journal-title":"Gastroenterology"},{"key":"e_1_3_2_149_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3616"},{"issue":"36","key":"e_1_3_2_150_2","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004732","article-title":"Transanal endoscopic microsurgery for advanced polyps and early cancers in the rectum\u2010Long\u2010term outcome: A STROBE compliant observational study","volume":"95","author":"Al\u2010Najami I","year":"2016","unstructured":"Al\u2010Najami I, Rancinger CP, Larsen MK, Thomassen N, Buch N, Baatrup G. Transanal endoscopic microsurgery for advanced polyps and early cancers in the rectum\u2010Long\u2010term outcome: A STROBE compliant observational study. Medicine (Baltimore). 2016;95((36)):e4732.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"e_1_3_2_151_2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/bjs.1800691019","article-title":"The mesorectum in rectal cancer surgery\u2013the clue to pelvic recurrence?","volume":"69","author":"Heald RJ","year":"1982","unstructured":"Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery\u2013the clue to pelvic recurrence? Br J Surg. 1982;69((10)):613\u20136.","journal-title":"Br J Surg"},{"issue":"1","key":"e_1_3_2_152_2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.annonc.2022.09.160","article-title":"Short\u2010term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2\u2010T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU\u2010TEM study)","volume":"34","author":"Serra\u2010Aracil X","year":"2023","unstructured":"Serra\u2010Aracil X, Pericay C, Badia\u2010Closa J, Golda T, Biondo S, Hernandez P, et\u00a0al. Short\u2010term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2\u2010T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU\u2010TEM study). Ann Oncol. 2023;34((1)):78\u201390.","journal-title":"Ann Oncol"},{"issue":"5","key":"e_1_3_2_153_2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051313","article-title":"Targeted Radiotherapy Using Contact X\u2010ray Brachytherapy 50 kV","volume":"14","author":"Gerard JP","year":"2022","unstructured":"Gerard JP, Myint AS, Barbet N, Dejean C, Thamphya B, Gal J, et\u00a0al. Targeted Radiotherapy Using Contact X\u2010ray Brachytherapy 50 kV. Cancers (Basel). 2022;14((5)).","journal-title":"Cancers (Basel)"},{"key":"e_1_3_2_154_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA3514","article-title":"Curative chemoradiation for low rectal cancer: Primary clinical outcomes from a multicenter phase II trial","author":"Jensen LH","year":"2022","unstructured":"Jensen LH, Risum S, Nielsen JD, Mynster T, Ploeen J, Rahr HB, et\u00a0al. Curative chemoradiation for low rectal cancer: Primary clinical outcomes from a multicenter phase II trial. Am Soc Clin Oncol. 2022:LBA3514.","journal-title":"Am Soc Clin Oncol"},{"issue":"16","key":"e_1_3_2_155_2","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1200\/JCO.2022.40.16_suppl.3512","article-title":"Contact x\u2010ray brachytherapy (Papillon) in addition to chemoradiotherapy to improve organ preservation in early cT2\u2010T3 rectal adenocarcinoma: The 3\u2010year results of OPERA randomized trial (NCT02505750)","volume":"40","author":"Gerard J\u2010P","year":"2022","unstructured":"Gerard J\u2010P, Barbet NN, Pac\u00e9\u2010Loscos T, Magn\u00e9 N, Serrand J, Mineur L, et\u00a0al. Contact x\u2010ray brachytherapy (Papillon) in addition to chemoradiotherapy to improve organ preservation in early cT2\u2010T3 rectal adenocarcinoma: The 3\u2010year results of OPERA randomized trial (NCT02505750). J Clin Oncol. 2022;40((16)_suppl):3512\u2010.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_156_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00439-3"},{"issue":"12","key":"e_1_3_2_157_2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41571-021-00538-5","article-title":"International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer","volume":"18","author":"Fokas E","year":"2021","unstructured":"Fokas E, Appelt A, Glynne\u2010Jones R, Beets G, Perez R, Garcia\u2010Aguilar J, et\u00a0al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol. 2021;18((12)):805\u201316.","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"e_1_3_2_158_2","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","article-title":"Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO\/ARO\/AIO\u201094 Randomized Phase III Trial After a Median Follow\u2010Up of 11 Years","volume":"30","author":"Sauer R","year":"2012","unstructured":"Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et\u00a0al. Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO\/ARO\/AIO\u201094 Randomized Phase III Trial After a Median Follow\u2010Up of 11 Years. J Clin Oncol. 2012;30((16)):1926\u201333.","journal-title":"J Clin Oncol"},{"issue":"28","key":"e_1_3_2_159_2","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","article-title":"Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3\u20104 rectal cancers: results of FFCD 9203","volume":"24","author":"G\u00e9rard JP","year":"2006","unstructured":"G\u00e9rard JP, Conroy T, Bonnetain F, Bouch\u00e9 O, Chapet O, Closon\u2010Dejardin MT, et\u00a0al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3\u20104 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24((28)):4620\u20135.","journal-title":"J Clin Oncol"},{"issue":"24","key":"e_1_3_2_160_2","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1200\/JCO.2005.02.113","article-title":"Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results\u2013EORTC 22921","volume":"23","author":"Bosset JF","year":"2005","unstructured":"Bosset JF, Calais G, Mineur L, Maingon P, Radosevic\u2010Jelic L, Daban A, et\u00a0al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results\u2013EORTC 22921. J Clin Oncol. 2005;23((24)):5620\u20137.","journal-title":"J Clin Oncol"},{"issue":"6","key":"e_1_3_2_161_2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1470-2045(12)70116-X","article-title":"Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non\u2010inferiority, phase 3 trial","volume":"13","author":"Hofheinz RD","year":"2012","unstructured":"Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et\u00a0al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non\u2010inferiority, phase 3 trial. Lancet Oncol. 2012;13((6)):579\u201388.","journal-title":"Lancet Oncol"},{"issue":"36","key":"e_1_3_2_162_2","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1200\/JCO.20.01932","article-title":"Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer","volume":"38","author":"Zhu J","year":"2020","unstructured":"Zhu J, Liu A, Sun X, Liu L, Zhu Y, Zhang T, et\u00a0al. Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer. J Clin Oncol. 2020;38((36)):4231\u20139.","journal-title":"J Clin Oncol"},{"issue":"34","key":"e_1_3_2_163_2","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.18.02309","article-title":"Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial","volume":"37","author":"Deng Y","year":"2019","unstructured":"Deng Y, Chi P, Lan P, Wang L, Chen W, Cui L, et\u00a0al. Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial. J Clin Oncol. 2019;37((34)):3223\u201333.","journal-title":"J Clin Oncol"},{"issue":"8","key":"e_1_3_2_164_2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(15)00004-2","article-title":"Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial","volume":"16","author":"Garcia\u2010Aguilar J","year":"2015","unstructured":"Garcia\u2010Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG, et\u00a0al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16((8)):957\u201366.","journal-title":"Lancet Oncol"},{"issue":"6","key":"e_1_3_2_165_2","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0071","article-title":"Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer","volume":"4","author":"Cercek A","year":"2018","unstructured":"Cercek A, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM, et\u00a0al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncol. 2018;4((6)):e180071.","journal-title":"JAMA Oncol"},{"issue":"23","key":"e_1_3_2_166_2","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy","volume":"40","author":"Garcia\u2010Aguilar J","year":"2022","unstructured":"Garcia\u2010Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et\u00a0al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022;40((23)):2546\u201356.","journal-title":"J Clin Oncol"},{"issue":"3","key":"e_1_3_2_167_2","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/j.ijrobp.2012.01.023","article-title":"Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas","volume":"83","author":"Gay HA","year":"2012","unstructured":"Gay HA, Barthold HJ, O'Meara E, Bosch WR, El Naqa I, Al\u2010Lozi R, et\u00a0al. Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys. 2012;83((3)):e353\u201362.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"23","key":"e_1_3_2_168_2","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer","volume":"350","author":"Andr\u00e9 T","year":"2004","unstructured":"Andr\u00e9 T, Boni C, Mounedji\u2010Boudiaf L, Navarro M, Tabernero J, Hickish T, et\u00a0al. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. N Engl J Med. 2004;350((23)):2343\u201351.","journal-title":"N Engl J Med"},{"issue":"11","key":"e_1_3_2_169_2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S1470-2045(14)70377-8","article-title":"Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open\u2010label, multicentre, phase 2, randomised controlled trial","volume":"15","author":"Hong YS","year":"2014","unstructured":"Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, et\u00a0al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open\u2010label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014;15((11)):1245\u201353.","journal-title":"Lancet Oncol"},{"issue":"14","key":"e_1_3_2_170_2","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJM199704033361402","article-title":"Improved survival with preoperative radiotherapy in resectable rectal cancer","volume":"336","author":"Swedish Rectal Cancer T","year":"1997","unstructured":"Swedish Rectal Cancer T , Cedermark B, Dahlberg M, Glimelius B, Pahlman L, Rutqvist LE, et\u00a0al. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336((14)):980\u20137.","journal-title":"N Engl J Med"},{"issue":"6","key":"e_1_3_2_171_2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","article-title":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12\u2010year follow\u2010up of the multicentre, randomised controlled TME trial","volume":"12","author":"van Gijn W","year":"2011","unstructured":"van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et\u00a0al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12\u2010year follow\u2010up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12((6)):575\u201382.","journal-title":"Lancet Oncol"},{"issue":"10","key":"e_1_3_2_172_2","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/bjs.5506","article-title":"Long\u2010term results of a randomized trial comparing preoperative short\u2010course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer","volume":"93","author":"Bujko K","year":"2006","unstructured":"Bujko K, Nowacki MP, Nasierowska\u2010Guttmejer A, Michalski W, Bebenek M, Kryj M. Long\u2010term results of a randomized trial comparing preoperative short\u2010course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93((10)):1215\u201323.","journal-title":"Br J Surg"},{"issue":"31","key":"e_1_3_2_173_2","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1200\/JCO.2012.42.9597","article-title":"Randomized Trial of Short\u2010Course Radiotherapy Versus Long\u2010Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans\u2010Tasman Radiation Oncology Group Trial 01.04","volume":"30","author":"Ngan SY","year":"2012","unstructured":"Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et\u00a0al. Randomized Trial of Short\u2010Course Radiotherapy Versus Long\u2010Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans\u2010Tasman Radiation Oncology Group Trial 01.04. J Clin Oncol. 2012;30((31)):3827\u201333.","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_3_2_174_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short\u2010course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open\u2010label, phase 3 trial","volume":"22","author":"Bahadoer RR","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM\u2010K, et\u00a0al. Short\u2010course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open\u2010label, phase 3 trial. Lancet Oncol. 2021;22((1)):29\u201342.","journal-title":"Lancet Oncol"},{"issue":"4","key":"e_1_3_2_175_2","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa2303269","article-title":"Preoperative Treatment of Locally Advanced Rectal Cancer","volume":"389","author":"Schrag D","year":"2023","unstructured":"Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, et\u00a0al. Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023;389((4)):322\u201334.","journal-title":"N Engl J Med"},{"issue":"6","key":"e_1_3_2_176_2","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1053\/j.seminoncol.2006.10.019","article-title":"Can pelvic radiotherapy be omitted in select patients with rectal cancer?","volume":"33","author":"Lai LL","year":"2006","unstructured":"Lai LL, Fuller CD, Kachnic LA, Thomas CR, Jr. Can pelvic radiotherapy be omitted in select patients with rectal cancer? Semin Oncol. 2006;33((6) Suppl 11):S70\u20134.","journal-title":"Semin Oncol"},{"issue":"10","key":"e_1_3_2_177_2","first-page":"1785","article-title":"Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis","volume":"22","author":"Gunderson LL","year":"2004","unstructured":"Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, et\u00a0al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004;22((10)):1785\u201396.","journal-title":"J Clin Oncol"},{"issue":"7","key":"e_1_3_2_178_2","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1200\/JCO.2002.07.132","article-title":"Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control\u2013final report of intergroup 0114","volume":"20","author":"Tepper JE","year":"2002","unstructured":"Tepper JE, O'Connell M, Niedzwiecki D, Hollis DR, Benson AB, 3rd, Cummings B, et\u00a0al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control\u2013final report of intergroup 0114. J Clin Oncol. 2002;20((7)):1744\u201350.","journal-title":"J Clin Oncol"},{"issue":"5","key":"e_1_3_2_179_2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER\u2010PRODIGE 23): a multicentre, randomised, open\u2010label, phase 3 trial","volume":"22","author":"Conroy T","year":"2021","unstructured":"Conroy T, Bosset JF, Etienne PL, Rio E, Francois E, Mesgouez\u2010Nebout N, et\u00a0al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER\u2010PRODIGE 23): a multicentre, randomised, open\u2010label, phase 3 trial. Lancet Oncol. 2021;22((5)):702\u201315.","journal-title":"Lancet Oncol"},{"issue":"5","key":"e_1_3_2_180_2","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.23.01208","article-title":"Long\u2010Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial","volume":"42","author":"Verheij FS","year":"2024","unstructured":"Verheij FS, Omer DM, Williams H, Lin ST, Qin LX, Buckley JT, et\u00a0al. Long\u2010Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. J Clin Oncol. 2024;42((5)):500\u20136.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_181_2","doi-asserted-by":"crossref","first-page":"LBA3513","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA3513","article-title":"A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study final results","volume":"40","author":"Tamberi S","year":"2022","unstructured":"Tamberi S, Grassi E, Zingaretti C, Papiani G, Pini S, Corbelli J, et\u00a0al. A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study final results. J Clin Oncol. 2022;40:LBA3513\u2013LBA.","journal-title":"J Clin Oncol"},{"issue":"16","key":"e_1_3_2_182_2","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2022.40.16_suppl.3611","article-title":"Total neoadjuvant chemoradiation combined with neoadjuvant PD\u20101 blockade for patients with pMMR, high\u2010risk, and locally advanced middle to low rectal cancer","volume":"40","author":"WU A","year":"2022","unstructured":"WU A, Li Y, Ji D, Zhang L, Zhang X, Cai Y, et\u00a0al. Total neoadjuvant chemoradiation combined with neoadjuvant PD\u20101 blockade for patients with pMMR, high\u2010risk, and locally advanced middle to low rectal cancer. J Clin Oncol. 2022;40((16)_suppl):3611.","journal-title":"J Clin Oncol"},{"issue":"15","key":"e_1_3_2_183_2","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1200\/JCO.2021.39.15_suppl.3511","article-title":"Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA study","volume":"39","author":"Salvatore L","year":"2021","unstructured":"Salvatore L, Bensi M, Corallo S, Bergamo F, Pellegrini I, Rasola C, et\u00a0al. Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA study. J Clin Oncol. 2021;39((15)_suppl):3511.","journal-title":"J Clin Oncol"},{"issue":"4","key":"e_1_3_2_184_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1200\/JCO.2022.40.4_suppl.099","article-title":"Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR\u20102","volume":"40","author":"George TJ","year":"2022","unstructured":"George TJ, Yothers G, Jacobs SA, Finley GG, Wade JL, Rocha Lima CMSP, et\u00a0al. Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR\u20102. J Clin Oncol. 2022;40((4)_suppl):99\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"e_1_3_2_185_2","article-title":"Phase II, single\u2010arm trial of preoperative short\u2010course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer","volume":"9","author":"Lin Z","year":"2021","unstructured":"Lin Z, Cai M, Zhang P, Li G, Liu T, Li X, et\u00a0al. Phase II, single\u2010arm trial of preoperative short\u2010course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer. J Immunother Cancer. 2021;9((11)).","journal-title":"J Immunother Cancer"},{"key":"e_1_3_2_186_2","doi-asserted-by":"crossref","first-page":"S1266","DOI":"10.1016\/j.annonc.2023.10.017","article-title":"LBA25 Neoadjuvant short\u2010course radiotherapy followed by camrelizumab plus chemotherapy versus long\u2010course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: A randomized phase III trial (UNION)","volume":"34","author":"Zhang T","year":"2023","unstructured":"Zhang T, Tao K, Lin Z, Zhang P, Yin Y, Chi P, et\u00a0al. LBA25 Neoadjuvant short\u2010course radiotherapy followed by camrelizumab plus chemotherapy versus long\u2010course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: A randomized phase III trial (UNION). Ann Oncol. 2023;34:S1266\u20137.","journal-title":"Ann Oncol"},{"issue":"5","key":"e_1_3_2_187_2","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10350-004-0909-0","article-title":"Surgery for locally recurrent rectal cancer","volume":"48","author":"Boyle KM","year":"2005","unstructured":"Boyle KM, Sagar PM, Chalmers AG, Sebag\u2010Montefiore D, Cairns A, Eardley I. Surgery for locally recurrent rectal cancer. Dis Colon Rectum. 2005;48((5)):929\u201337.","journal-title":"Dis Colon Rectum"},{"issue":"4","key":"e_1_3_2_188_2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/01.SLA.0000059972.90598.5F","article-title":"Curative potential of multimodality therapy for locally recurrent rectal cancer","volume":"237","author":"Hahnloser D","year":"2003","unstructured":"Hahnloser D, Nelson H, Gunderson LL, Hassan I, Haddock MG, O'Connell MJ, et\u00a0al. Curative potential of multimodality therapy for locally recurrent rectal cancer. Ann Surg. 2003;237((4)):502\u20138.","journal-title":"Ann Surg"},{"issue":"10","key":"e_1_3_2_189_2","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s10350-004-0677-x","article-title":"Colorectal cancer pelvic recurrences: determinants of resectability","volume":"47","author":"Moore HG","year":"2004","unstructured":"Moore HG, Shoup M, Riedel E, Minsky BD, Alektiar KM, Ercolani M, et\u00a0al. Colorectal cancer pelvic recurrences: determinants of resectability. Dis Colon Rectum. 2004;47((10)):1599\u2013606.","journal-title":"Dis Colon Rectum"},{"issue":"3","key":"e_1_3_2_190_2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s10350-007-9152-9","article-title":"Extended radical resection: the choice for locally recurrent rectal cancer","volume":"51","author":"Heriot AG","year":"2008","unstructured":"Heriot AG, Byrne CM, Lee P, Dobbs B, Tilney H, Solomon MJ, et\u00a0al. Extended radical resection: the choice for locally recurrent rectal cancer. Dis Colon Rectum. 2008;51((3)):284\u201391.","journal-title":"Dis Colon Rectum"},{"issue":"8","key":"e_1_3_2_191_2","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1007\/s10350-004-6363-1","article-title":"Pelvic exenteration and sacral resection for locally advanced primary and recurrent rectal cancer","volume":"45","author":"Yamada K","year":"2002","unstructured":"Yamada K, Ishizawa T, Niwa K, Chuman Y, Aikou T. Pelvic exenteration and sacral resection for locally advanced primary and recurrent rectal cancer. Dis Colon Rectum. 2002;45((8)):1078\u201384.","journal-title":"Dis Colon Rectum"},{"issue":"5","key":"e_1_3_2_192_2","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1245\/s10434-009-0861-2","article-title":"Management of recurrent rectal cancer","volume":"17","author":"Bouchard P","year":"2010","unstructured":"Bouchard P, Efron J. Management of recurrent rectal cancer. Ann Surg Oncol. 2010;17((5)):1343\u201356.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"e_1_3_2_193_2","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/DCR.0b013e3181e10b0e","article-title":"Clinical algorithms for the surgical management of locally recurrent rectal cancer","volume":"53","author":"Mirnezami AH","year":"2010","unstructured":"Mirnezami AH, Sagar PM, Kavanagh D, Witherspoon P, Lee P, Winter D. Clinical algorithms for the surgical management of locally recurrent rectal cancer. Dis Colon Rectum. 2010;53((9)):1248\u201357.","journal-title":"Dis Colon Rectum"},{"issue":"2","key":"e_1_3_2_194_2","first-page":"12","article-title":"Practical genetics of colorectal cancer","volume":"2","author":"Lynch HT","year":"2013","unstructured":"Lynch HT, Shaw TG. Practical genetics of colorectal cancer. Chin Clin Oncol. 2013;2((2)):12.","journal-title":"Chin Clin Oncol"},{"issue":"5","key":"e_1_3_2_195_2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1001\/jama.2012.8780","article-title":"Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas","volume":"308","author":"Grover S","year":"2012","unstructured":"Grover S, Kastrinos F, Steyerberg EW, Cook EF, Dewanwala A, Burbidge LA, et\u00a0al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA. 2012;308((5)):485\u201392.","journal-title":"JAMA"},{"issue":"3","key":"e_1_3_2_196_2","first-page":"270","article-title":"Clinical and genetic phenotype of familial adenomatous polyposis and its subtypes","volume":"22","author":"Yang S","year":"2007","unstructured":"Yang S, Cai S, Zhang S. Clinical and genetic phenotype of familial adenomatous polyposis and its subtypes. J Pract Oncol. 2007;22((3)):270\u201373.","journal-title":"J Pract Oncol"},{"key":"e_1_3_2_197_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2006.07.004"},{"issue":"6","key":"e_1_3_2_198_2","first-page":"1157","article-title":"Research on the fundus fluorescein angiography in congenital hypertrophy of the retinal pigment epithelium in patients with familial adenomatous polyposis","volume":"10","author":"Yan D","year":"2020","unstructured":"Yan D, Yu X, Xiao\u2010Dong X. Research on the fundus fluorescein angiography in congenital hypertrophy of the retinal pigment epithelium in patients with familial adenomatous polyposis. International Eye Science. 2020;10((6)):1157\u20139.","journal-title":"International Eye Science"},{"issue":"36","key":"e_1_3_2_199_2","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.11569\/wcjd.v18.i36.3922","article-title":"Clinical features of Gardner syndrome and Turcot syndrome in Chinese population:an analysis of 93 cases","volume":"18","author":"Cao HL","year":"2010","unstructured":"Cao HL, Wang BM, Cao XC. Clinical features of Gardner syndrome and Turcot syndrome in Chinese population:an analysis of 93 cases. World Chinese J Digestol. 2010;18((36)):3922\u20135.","journal-title":"World Chinese J Digestol"},{"issue":"5","key":"e_1_3_2_200_2","first-page":"541","article-title":"Familial adenomatous polyposis\u2010associated desmoid tumors","volume":"27","author":"Lou Z","year":"2006","unstructured":"Lou Z, Yu ED, Meng RG. Familial adenomatous polyposis\u2010associated desmoid tumors. Acad J Second Mil Med Univ. 2006;27((5)):541\u20133.","journal-title":"Acad J Second Mil Med Univ"},{"issue":"9","key":"e_1_3_2_201_2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJMoa025283","article-title":"Multiple colorectal adenomas, classic adenomatous polyposis, and germ\u2010line mutations in MYH","volume":"348","author":"Sieber OM","year":"2003","unstructured":"Sieber OM, Lipton L, Crabtree M, Heinimann K, Fidalgo P, Phillips RK, et\u00a0al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ\u2010line mutations in MYH. N Engl J Med. 2003;348((9)):791\u20139.","journal-title":"N Engl J Med"},{"issue":"16","key":"e_1_3_2_202_2","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1001\/jama.293.16.1979","article-title":"Lower cancer incidence in Amsterdam\u2010I criteria families without mismatch repair deficiency: familial colorectal cancer type X","volume":"293","author":"Lindor NM","year":"2005","unstructured":"Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J, et\u00a0al. Lower cancer incidence in Amsterdam\u2010I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA. 2005;293((16)):1979\u201385.","journal-title":"JAMA"},{"issue":"3","key":"e_1_3_2_203_2","first-page":"21","article-title":"Research progress of Lynch syndrome in China","volume":"2015","author":"Li XF","unstructured":"Li XF, Yuan Y. Research progress of Lynch syndrome in China. Chinese J Colorect Dis (Electronic Edition). 2015((3)):21\u20136.","journal-title":"Chinese J Colorect Dis (Electronic Edition)"},{"issue":"15","key":"e_1_3_2_204_2","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jama.2012.13088","article-title":"Identification of Lynch syndrome among patients with colorectal cancer","volume":"308","author":"Moreira L","year":"2012","unstructured":"Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA, et\u00a0al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA. 2012;308((15)):1555\u201365.","journal-title":"JAMA"},{"issue":"3","key":"e_1_3_2_205_2","first-page":"191","article-title":"Implementation of screening standards for hereditary colorectal cancer in the Chinese population","volume":"26","author":"National Collaborative Group on Hereditary Colorectal Cancer","year":"2004","unstructured":"National Collaborative Group on Hereditary Colorectal Cancer . Implementation of screening standards for hereditary colorectal cancer in the Chinese population. Chinese J Oncol. 2004;26((3)):191\u20132.","journal-title":"Chinese J Oncol"},{"issue":"1","key":"e_1_3_2_206_2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ng.283","article-title":"Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1","volume":"41","author":"Ligtenberg MJ","year":"2009","unstructured":"Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, et\u00a0al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet. 2009;41((1)):112\u20137.","journal-title":"Nat Genet"},{"issue":"2","key":"e_1_3_2_207_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1053\/j.gastro.2008.04.026","article-title":"The clinical phenotype of Lynch syndrome due to germ\u2010line PMS2 mutations","volume":"135","author":"Senter L","year":"2008","unstructured":"Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, et\u00a0al. The clinical phenotype of Lynch syndrome due to germ\u2010line PMS2 mutations. Gastroenterology. 2008;135((2)):419\u201328.","journal-title":"Gastroenterology"},{"issue":"1","key":"e_1_3_2_208_2","first-page":"36","article-title":"Clinical phenotype of Chinese hereditary nonpolyposis colorectal cancer (HNPCC) families","volume":"28","author":"Yuan Y","year":"2006","unstructured":"Yuan Y, Cao WM, Cai SR, Zhang SZ. Clinical phenotype of Chinese hereditary nonpolyposis colorectal cancer (HNPCC) families. Chinese J Oncol. 2006;28((1)):36\u20138.","journal-title":"Chinese J Oncol"},{"key":"e_1_3_2_209_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043146"},{"issue":"2","key":"e_1_3_2_210_2","first-page":"192","article-title":"Research Advance of Muir\u2010Torre Syndrome","volume":"12","author":"Wang SL","year":"2005","unstructured":"Wang SL, Da JP, Gu GL. Research Advance of Muir\u2010Torre Syndrome. Chinese J Bases & Clinics Gen Surg. 2005;12((2)):192\u20134.","journal-title":"Chinese J Bases & Clinics Gen Surg"},{"issue":"3","key":"e_1_3_2_211_2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jnci\/djk033","article-title":"Performance of different microsatellite marker panels for detection of mismatch repair\u2010deficient colorectal tumors","volume":"99","author":"Xicola RM","year":"2007","unstructured":"Xicola RM, Llor X, Pons E, Castells A, Alenda C, Pinol V, et\u00a0al. Performance of different microsatellite marker panels for detection of mismatch repair\u2010deficient colorectal tumors. J Natl Cancer Inst. 2007;99((3)):244\u201352.","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"e_1_3_2_212_2","first-page":"5248","article-title":"A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer","volume":"58","author":"Boland CR","year":"1998","unstructured":"Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et\u00a0al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58((22)):5248\u201357.","journal-title":"Cancer Res"},{"issue":"6","key":"e_1_3_2_213_2","first-page":"603","article-title":"The analysis for identifying large DNA fragment aberrations of MSH2 and MLH1 genes from familial colorectal cancer in China","volume":"22","author":"Zhu M","year":"2005","unstructured":"Zhu M, Liu XR, Huang YQ, Yuan Y, Li JT, Zhang XM, et\u00a0al. The analysis for identifying large DNA fragment aberrations of MSH2 and MLH1 genes from familial colorectal cancer in China. Chinese J Med Genet. 2005;22((6)):603\u20136.","journal-title":"Chinese J Med Genet"},{"issue":"08","key":"e_1_3_2_214_2","first-page":"526","article-title":"Clinical meta\u2010analysis of melanotic polyp syndrome in mainland China","volume":"2008","author":"Dai YC","unstructured":"Dai YC, Xie JP, Zeng W, Fu YK, Chen ZX. Clinical meta\u2010analysis of melanotic polyp syndrome in mainland China. J Clin Intern Med. 2008((08)):526\u20137.","journal-title":"J Clin Intern Med"},{"issue":"21","key":"e_1_3_2_215_2","first-page":"1639","article-title":"Mutational analysis of the STK11 gene in a family line with Peutz\u2010Jeghers syndrome","volume":"47","author":"Kang LC","year":"2002","unstructured":"Kang LC, Zhao XR, Zhou YS, Jia YX, Kang SH, Chen Z, et\u00a0al. Mutational analysis of the STK11 gene in a family line with Peutz\u2010Jeghers syndrome. Science Bulletin. 2002;47((21)):1639\u201343.","journal-title":"Science Bulletin"},{"issue":"1","key":"e_1_3_2_216_2","first-page":"64","article-title":"Consensus on clinical diagnosis, treatment and pedigree management of hereditary colorectal cancer in China","volume":"40","author":"Genetics Group of the Colorectal Cancer Professional Committee of the Chinese Anti\u2010Cancer Association","year":"2018","unstructured":"Genetics Group of the Colorectal Cancer Professional Committee of the Chinese Anti\u2010Cancer Association . Consensus on clinical diagnosis, treatment and pedigree management of hereditary colorectal cancer in China. Chinese J Oncol. 2018;40((1)):64\u201377.","journal-title":"Chinese J Oncol"}],"container-title":["Cancer Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1002\/cac2.12639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:45:22Z","timestamp":1773823522000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1002\/cac2.12639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":215,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/cac2.12639"],"URL":"https:\/\/doi.org\/10.1002\/cac2.12639","relation":{},"ISSN":["2523-3548"],"issn-type":[{"value":"2523-3548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]},"assertion":[{"value":"2024-11-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}